User profiles for Carolin Zitzmann
Carolin ZitzmannLos Alamos National Laboratory Verified email at lanl.gov Cited by 441 |
[HTML][HTML] The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
…, J Varriale, EJ Fray, C Zitzmann… - The Journal of …, 2023 - Am Soc Clin Investig
HIV-1 persists in a latent reservoir in resting CD4 + T cells despite antiretroviral therapy (ART).
The reservoir decays slowly over the first 7 years of ART (t 1/2 = 44 months). However, …
The reservoir decays slowly over the first 7 years of ART (t 1/2 = 44 months). However, …
In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness
R Ke, C Zitzmann, DD Ho… - Proceedings of the …, 2021 - National Acad Sciences
The within-host viral kinetics of SARS-CoV-2 infection and how they relate to a person’s
infectiousness are not well understood. This limits our ability to quantify the impact of …
infectiousness are not well understood. This limits our ability to quantify the impact of …
[HTML][HTML] Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation
…, P V'kovski, K Hörmann, AC Müller, C Zitzmann… - Nature …, 2021 - nature.com
Double membrane vesicles (DMVs) serve as replication organelles of plus-strand RNA
viruses such as hepatitis C virus (HCV) and SARS-CoV-2. Viral DMVs are morphologically …
viruses such as hepatitis C virus (HCV) and SARS-CoV-2. Viral DMVs are morphologically …
[PDF][PDF] Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants
The decay kinetics of HIV-1-infected cells are critical to understand virus persistence. We
evaluated the frequency of simian immunodeficiency virus (SIV)-infected cells for 4 years of …
evaluated the frequency of simian immunodeficiency virus (SIV)-infected cells for 4 years of …
[HTML][HTML] Mathematical analysis of viral replication dynamics and antiviral treatment strategies: from basic models to age-based multi-scale modeling
C Zitzmann, L Kaderali - Frontiers in microbiology, 2018 - frontiersin.org
Viral infectious diseases are a global health concern, as is evident by recent outbreaks of the
middle east respiratory syndrome, Ebola virus disease, and re-emerging zika, dengue, and …
middle east respiratory syndrome, Ebola virus disease, and re-emerging zika, dengue, and …
Kinetics of SARS-CoV-2 infection in the human upper and lower respiratory tracts and their relationship with infectiousness
SARS-CoV-2 is a human pathogen that causes infection in both the upper respiratory tract (URT)
and the lower respiratory tract (LRT). The viral kinetics of SARS-CoV-2 infection and …
and the lower respiratory tract (LRT). The viral kinetics of SARS-CoV-2 infection and …
[HTML][HTML] A coupled mathematical model of the intracellular replication of dengue virus and the host cell immune response to infection
C Zitzmann, B Schmid, A Ruggieri… - Frontiers in …, 2020 - frontiersin.org
Dengue virus (DV) is a positive-strand RNA virus of the Flavivirus genus. It is one of the most
prevalent mosquito-borne viruses, infecting globally 390 million individuals per year. The …
prevalent mosquito-borne viruses, infecting globally 390 million individuals per year. The …
[HTML][HTML] How robust are estimates of key parameters in standard viral dynamic models?
Mathematical models of viral infection have been developed, fitted to data, and provide insight
into disease pathogenesis for multiple agents that cause chronic infection, including HIV, …
into disease pathogenesis for multiple agents that cause chronic infection, including HIV, …
[HTML][HTML] Automated characterization and parameter-free classification of cell tracks based on local migration behavior
Cell migration is the driving force behind the dynamics of many diverse biological processes.
Even though microscopy experiments are routinely performed today by which populations …
Even though microscopy experiments are routinely performed today by which populations …
[HTML][HTML] Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
To mitigate the loss of lives during the COVID-19 pandemic, emergency use authorization
was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment …
was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment …